Immunosuppressants drugs - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.02 [0.62, 1.68]< 10%1 study (1/-)47.2 %some concernnot evaluable moderatecrucial-
deaths 0.88 [0.74, 1.04]< 120%17 studies (17/-)93.1 %highlow lowcrucial-
deaths (time to event analysis only) 1.16 [0.73, 1.84]< 10%1 study (1/-)26.3 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.78 [0.59, 1.02]< 10%6 studies (6/-)96.6 %some concernnot evaluable moderateimportant-
clinical improvement 1.29 [1.10, 1.52]> 133%9 studies (9/-)99.9 %highnot evaluable lowimportant-
clinical improvement (14-day) 1.86 [1.20, 2.87]> 10%1 study (1/-)99.7 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.10 [0.94, 1.29]> 10%4 studies (4/-)88.7 %highnot evaluable lowimportant-
death or ventilation 0.85 [0.66, 1.08]< 155%9 studies (9/-)90.8 %highnot evaluable lowimportant-
hospital discharge 1.16 [0.90, 1.49]> 10%1 study (1/-)87.9 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.61 [0.41, 0.89]< 142%6 studies (6/-)99.4 %highnot evaluable lowimportant-
ICU admission 0.80 [0.29, 2.16]< 177%2 studies (2/-)67.1 %some concernnot evaluable moderatenon important-
off oxygenation 1.46 [0.79, 2.68]> 128%2 studies (2/-)88.7 %highnot evaluable lownon important-

safety endpoints 00

serious adverse events 1.00 [0.76, 1.31]< 10%5 studies (5/-)51.1 %some concernnot evaluable moderateimportant-
adverse events 1.43 [0.84, 2.40]< 170%5 studies (5/-)9.2 %some concernserious moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.